LDH hybrid thermosensitive hydrogel for intravaginal delivery of anti-HIV drugs (Retracted Article)
LDH hybrid thermosensitive hydrogel for intravaginal delivery of anti-HIV drugs (Retracted Article)
复制标题
LDH混合热敏水凝胶用于阴道内递送抗HIV药物
DOI：
10.1080/21691401.2019.1596935
复制
发表时间：
2019-01-01
影响因子：
5.8
通讯作者：
Sun, Yong
中科院分区：
文献类型：
--
作者：
Tian, Wenxue;Han, Shangcong;Sun, Yong
基于水凝胶的杀微生物剂因其使用方便、释药时间长等优点，已成为预防HIV复制和传播的有效途径。在这项研究中，由纳米级层状双氢氧化物和泊洛沙姆407（P407）构成的杂化温敏水凝胶被构建，并与疏水和亲水药物共负载。LDH-P407水凝胶可在体温下实现溶胶-凝胶转变。体内实验表明，LDH-P407水凝胶可通过阴道给药实现茶黄素和尼罗红（疏水性药物模型）向血液中的控释，同时该水凝胶对粘膜几乎没有刺激性。此外，体外实验显示负载硝非韦罗的LDH-P407水凝胶能够特异性结合DC细胞的共受体CCR 5。因此，LDH-P407水凝胶将是一个有前途的载体，用于阴道内递送抗HIV药物。
Microbicides based on hydrogel have become an effective way to prevent the HIV replication and transmission because of their convenience and prolonging drug release. In this study, a hybrid thermo-sensitive hydrogel constituted by nanosized layered double hydroxides and poloxamer 407 (P407) was constructed and co-loaded with both hydrophobic and hydrophilic drug. The LDH-P407 hydrogel could achieve sol-gel transition at body temperature. The in vivo experiment showed that LDH-P407 hydrogel can achieve controlled release of theaflavin and Nile red (hydrophobic drug model) into blood by vaginal drug delivery, meanwhile the hydrogel showed barely mucosal irritation. In addition, ex vivo experiment showed that the nifeviroc-loaded LDH-P407 hydrogel was able to specifically bind co-receptor CCR5 of DCs cells. Therefore, the LDH-P407 hydrogel would be a promising carrier for intravaginal delivery of anti-HIV drugs.